Increased HYAL1 levels were found to correlate with tumor aggressiveness and poor survival in head and neck, prostate and bladder cancer [7–9], whereas HYAL1 expression was decreased in advanced ovarian carcinomas and in endometrial cancer [10–12]. Here, HYAL1 is linked to urinary bladder cancer.